Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Abstract 470: Computational Identification of NKX2-5 Binding Sites and Downstream Gene Targets Using Transcription Factor Motif and Human Heart-specific Experimental Data
Tan, Nicholas Y. , Chung, Mina K. , Smith, Jonathan D. , Wagoner, David R. Van , Barnard, John

Mayo Clinic

Circulation Research | June 21, 2021 | Volume: 119 | Issue: suppl_1 | Pages: No page available

10.1161/res.119.suppl_1.470 Get It

Background: While NKX2-5 plays pivotal roles in human cardiac development and disease, no ChIP-Seq studies of NKX2-5 in human cardiac tissues currently exist, resulting in an incomplete understanding of its direct gene targets. Modern computational methods which identify binding sites using transcription factor motif and tissue-specific experimental data can help to fill this knowledge gap. Objective: To use computational methods to identify likely NKX2-5 binding sites and downstream gene targets using human heart-specific experimental data. Methods: Human cardiomyocyte DNAse hypersensitivity data (2 replicates) were downloaded from the Encyclopedia of DNA Elements (ENCODE) database. The position weight matrix (PWM) representing the transcription factor motif of NKX2-5 was obtained from JASPAR. We applied the Protein Interaction Quantification (PIQ) algorithm to detect NKX2-5 binding sites using the PWM and DNAse hypersensitivity data as inputs. RNA-Seq data from 108 human heart-specific samples (atrial appendages and left ventricles) were downloaded from the Genotype-Tissue Expression (GTEx) database. Protein-coding genes significantly expressed in the heart (RPKM <= 1 based on the GTEx RNA-Seq data) that were within 100kb of the predicted binding sites were then identified. Pathway analysis of these genes was performed using Ingenuity Pathway Analysis (IPA). Results: 1283 binding sites for NKX2-5 were discovered by PIQ. Of 12698 protein-coding, heart-expressed genes, 625 were within 100kb of these binding sites. The identified genes were highly enriched in physiologic categories like “Vasculogenesis” and “Development of Cardiovascular Tissue” (p = 2.36x10-9 and 2.31x10-8 respectively). Notable genes included: cardiac transcription factors (MEF2A, TBX20); growth factors (TGFB2, BMP2); muscle and ion channel function (ACTA2, BIN1), and; calcium signaling (CALM2, CAMK2D). Conclusion: By using computational analyses of transcription factor motif and human heart-specific experimental data, we have identified candidate downstream targets of NKX2-5. Future work will include validation studies in an external cohort and analysis of associations between these candidate genes and cardiac disease.
Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry
Shrader, Peter, Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Go, Alan S. , Piccini, Jonathan P. , Echouffo-Tcheugui, Justin B , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.127 Get It

Objective: Diabetes is a common among patients with atrial fibrillation (AF). However, little is known on the impact of diabetes on symptoms, health status, care and outcomes among AF patients. We assessed whether symptoms, health status, care and outcomes differ between AF patients with and without diabetes. Methods: This observational cohort study included 9,749 patients with AF from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation registry, a prospective, nationwide, multicenter outpatient registry of patients with incident and prevalent AF enrolled at 174 sites between June 2010 and August 2011. The outcomes were symptoms, health status, and AF treatment, as well as 2-year risks of death, readmission, thrombomebolic events, heart failure (HF) and AF progression. Results: Among AF patients; those with diabetes (29.5%) were younger and more likely to have hypertension, chronic kidney disease, HF, coronary heart disease, and stroke. Patients with diabetes had a lower Atrial Fibrillation Effects on Quality of Life score (80.6 [IQR: 62.5 - 92.6] vs. 82.4 [IQR: 67.6 -93.5]; P = 0.025), but a higher CHA 2 DS 2 -VASc score (5 [IQR: 4 - 6] vs. 4 [2 - 5]; P <0.0001) and were more likely to receive anticoagulation ( P <0.001). Diabetes was associated with higher mortality, with a greater overall (adjusted hazard ratio [aHR]: 1.63 [95% CI: 1.04-2.56] for age<70 vs. 1.25 [1.09-1.44] for age ≥70) and cardiovascular (2.20 [1.22-3.98] for age<70 vs. 1.24 [1.02-1.51] for age ≥70) mortality risks before age 70 years. Diabetes conferred a higher risk of non-cardiovascular (CV) death (1.29 [1.06-1.56]), sudden cardiac death (1.53 [1.04-2.26]), hospitalization (1.15 [1.09-1.22]), CV hospitalization (1.13 [1.05-1.22]) and non-CV and non-bleeding-related hospitalization (1.19 [1.10-1.30]); but no increase in risks of thromboembolic events, bleeding related hospitalization, new-onset HF, and AF progression. The use of oral anticoagulants (OAC) modifies the relation of diabetes and all-cause hospitalization, with a higher risk among those on OAC (1.21 [1.12-1.29]). Conclusions: Among patients with AF, diabetes was associated with worse AF symptoms and lower quality of life, as well an increased risk of death and hospitalizations, but not with the risk of thromboembolic or bleeding events.
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE
Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Ansell, Jack , Berger, Peter B. , Reiffel, James A. , Singer, Daniel E. , Kowey, Peter R. , Piccini, Jonathan P. , O’Brien, Emily C. , Kaufman, Brystana G. , Fonarow, Gregg C. , Naccarelli, Gerald V. , Mahaffey, Kenneth W. , Chan, Paul S. , Allen, Larry A. , Freeman, James V. , Gersh, Bernard J. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.057 Get It

Introduction: Patient understanding of available therapies for atrial fibrillation (AF) is foundational to shared medical decision making and long term medication adherence. Yet, there is a paucity of data regarding the extent to which patients newly diagnosed with AF in routine community practice understand their options. Hypotheses: 1) Understanding of warfarin, novel oral anticoagulants (NOAC), rhythm control therapy, cardioversion and radio frequency ablation changes little from baseline to 6 months and 2) treatment rates at 6 months are associated with patient understanding of therapies at baseline. Methods: We analyzed survey data from SATELLITE, a substudy of new-onset AF patients enrolled at 56 US sites participating in the ORBIT-AF registry. Patients were surveyed at the baseline and 6 month follow up clinic visit using Likert scales. Agreement between time points was assessed with the McNemar test, and the relationship between understanding and treatment was assessed only for the subset not on treatment at baseline. Results: Of 1000 patients enrolled in SATELLITE, 506 had 6-month survey data (data collection is continuing). Among these, the median age was 69.0 years (IQR 63.0 - 76.0) and 93.7% (474 of 506) were white. There was evidence of improvement in the self-reported understanding of warfarin and NOACs from baseline to 6 months, but not for rhythm control, ablation or cardioversion. The proportion reporting high understanding improved significantly for warfarin (p<.0001) and NOACs (p<.0001) from 47% (223 of 474) and 51% (245 of 481) at baseline to 60% (284 of 474) and 69% (332 of 481) at 6 months respectively (Figure 1). Patients with high understanding of the benefits of ablation (p=0.0005) and options for ablation (p=0.0093) at baseline were more likely to have this therapy at the 6 month follow up (N=590), but improved understanding was not associated with increased use of warfarin/NOACs (N=83) or rhythm control (N=444). Conclusions: Patients with new-onset AF had improved self-reported understanding of some treatment options over the first 6-months from diagnosis; however, factors other than patient understanding may influence AF treatments received at 6 months. Patient understanding of AF treatments remains suboptimal at 6 months, and our results suggest a need for ongoing patient education.
Tryptamine Activates 5‐HT4 GPCR to Increase Secretion in the Mouse Proximal Colon
Bhattarai, Yogesh , Williams, Brianna B., Battaglioli, Eric , Grover, Madhusudhan, Whitaker, Weston R. , Akiba, Yasutada , Kaunitz, Jonathan D. , Sonnenburg, Justin L. , Farrugia, Gianrico , Kashyap, Purna , Linden, David R. , Kandimalla, Karunya K. , Zachos, Nicholas C. , Fischbach, Michael A.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.747.6 Get It

Background Microbial conversion of dietary substrate to bioactive molecules represents a potential regulatory mechanism by which gut microbes can alter intestinal physiology. Tryptamine, a monoamine structurally similar to serotonin (5‐HT), can be generated via decarboxylation of tryptophan by the gut bacteria but its physiological effect is not known. Aim To determine the effect of bacterial metabolite tryptamine on colonic secretion. Methods We mounted proximal colon mucosa‐submucosa preparations from germ free (GF), humanized (HM; ex‐GF colonized with human gut bacteria for 4–5 weeks), conventionally raised WT and 5‐HT4 receptor knockout (5‐HT4R −/− ) male mice in the Ussing chamber. The change in short circuit current (ΔIsc) was determined in response to application of increasing concentrations of tryptamine (3μM – 3mM) on the submucosal (basolateral) side either alone or in the presence of 5‐HT3R or 5‐HT4R antagonist, ondansetron (100nM) and GR‐113808 (30nM) respectively, with and without TTX (500nM). Colonoids (3‐dimensional epithelial organoids derived from colon) from GF and HM were used for swelling assay and ELISA based cAMP measurement. Results Tryptamine application significantly increased Isc in both GF and HM mice (n=6, P < 0.05, two‐way ANOVA with Bonferroni post‐hoc). Tryptamine mediated ΔIsc response was not significantly affected by amiloride, an inhibitor of epithelial sodium channels and Na + /H + exchangers, which are primarily responsible for absorption but was significantly decreased by 5‐Nitro‐2‐(3‐phenylpropylamino) benzoic acid (NPPB; anion blocker), a calcium‐sensitive chloride channel and sodium bicarbonate exchanger inhibitor responsible for anionic secretion in both GF and HM mice (n=4, P < 0.05, two‐way ANOVA with Bonferroni post‐hoc). Tryptamine evoked ΔIsc was not inhibited by 5‐HT3R (n=4, P > 0.05) but completely blocked by 5‐HT4R antagonist and was absent in 5HT4R knock out mice suggesting that the effect of tryptamine is mediated via 5HT4R. The increase in Isc in response to tryptamine and its inhibition by 5‐HT4R antagonist was also seen in presence of TTX (neuronal blocker; n=4, one‐way ANOVA , P < 0.05) suggesting that the epithelial 5‐HT4R alone can mediate the effect of tryptamine. Application of tryptamine (1mM) for 30 minutes led to a significant increase in the surface area of fluorescein labelled colonoids (n=5, one‐way ANOVA , P < 0.05), similar to forskolin, when compared to vehicle treated and 5HT4R antagonist pre‐treated GF and HM colonoids. Colonoids incubated with tryptamine (1mM) for 60 minutes had significantly higher cAMP levels (normalized to forskolin) compared to vehicle treated GF and HM colonoids, confirming that tryptamine activates 5‐HT4 GPCR (n=3, student's t‐test, P < 0.05). Conclusion Tryptamine, a tryptophan‐derived microbial metabolite, increases colonic secretion via 5HT4 GPCR activation. The identification of a bacterial metabolite activating a host GPCR to alter GI function represents an important advance in the field, and provides a distinct example of small molecule mediated host‐microbe interaction. Engineered probiotics producing tryptamine could be used as therapeutics in diseases associated with constipation. Support or Funding Information NIH DK111850, DK114007 (PCK) This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Systemic misfolding of immunoglobulins in the test tube and in the cell
Dick, Christopher J., Blancas‐Mejía, Luis M. , Redhage, Keely R., Jordan, Torri L., Williams, Angela, Ramı́rez-Alvarado, Marina , Misra, Pinaki , Lin, Yi , Wall, Jonathan S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.247.3 Get It

Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging
Adegunsoye, Ayodeji , Cannon, Brenna, Vij, Rekha, King, Christopher S. , Montner, Steven M. , Thirkateh, Prahasit , Barnett, Scott D. , Karwoski, Ronald A., Bartholmai, Brian J. , Strek, Mary E. , Nathan, Steven D. , Karwoski, Ronald, Bartholmai, Brian J , Chung, Jonathan Hero , Oldham, Justin M

Mayo Clinic

Journal of Clinical Medicine | June 17, 2021 | Volume: 10 | Issue: 12 | Pages: 2663

10.3390/jcm10122663 | PMID 34204184 Get It

A usual interstitial pneumonia (UIP) imaging pattern can be seen in both idiopathic pulmonary fibrosis (IPF) and connective tissue disease-related interstitial lung disease (CTD-ILD). The purpose of this multicenter study was to assess whether quantitative imaging data differ between IPF and CTD-ILD in the setting of UIP. Patients evaluated at two medical centers with CTD-ILD or IPF and a UIP pattern on CT or pathology served as derivation and validation cohorts. Chest CT data were quantitatively analyzed including total volumes of honeycombing, reticulation, ground-glass opacity, normal lung, and vessel related structures (VRS). VRS was compared with forced vital capacity percent predicted (FVC%) and percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO%). There were 296 subjects in total, with 40 CTD-ILD and 85 IPF subjects in the derivation cohort, and 62 CTD-ILD and 109 IPF subjects in the validation cohort. VRS was greater in IPF across the cohorts on univariate (p < 0.001) and multivariable (p < 0.001–0.047) analyses. VRS was inversely correlated with DLCO% in both cohorts on univariate (p < 0.001) and in the derivation cohort on multivariable analysis (p = 0.003) but not FVC%. Total volume of normal lung was associated with DLCO% (p < 0.001) and FVC% (p < 0.001–0.009) on multivariable analysis in both cohorts. VRS appears to have promise in differentiating CTD-ILD from IPF. The underlying pathophysiological relationship between VRS and ILD is complex and is likely not explained solely by lung fibrosis.
Neuroendovascular Management of Acute Ischemic Basilar Strokes: 2-Dimensional Operative Video
Porto, Guilherme , Sattur, Mithun G. , Kasab, Sami Al , Spiotta, Alejandro M , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Rodríguez, Rafael, Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Porto, Guilherme B F , Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael, Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | June 15, 2021 | Volume: 21 | Issue: 4 | Pages: E346-E347

10.1093/ons/opab180 | PMID 34131725 Get It

Abstract Basilar artery occlusions (BAOs) are devastating ischemic strokes that account for 1% of all strokes with high morbidity and mortality; however, neuroendovascular techniques such as ADAPT have recently revolutionized the clinical outcomes of these patients. 1-3 Common underlying pathology in patients with BAO include intracranial atherosclerotic disease (ICAD) as well as thromboembolic origin. 4 Basilar artery ICAD in a setting of acute stroke portends a poor prognosis and post-thrombectomy residual critical flow limiting stenosis treatment options, including balloon angioplasty with or without stent placement. 5-7 We present a video illustration of neuroendovascular technique and challenges encountered when managing this pathology. Image at 5:42 reprinted with permission from Alawieh et al, Lessons learned over more than 500 stroke thrombectomies using ADAPT with increasing aspiration catheter size, Neurosurgery , 86(1), 2020, pp. 61-70, with permission from the Congress of Neurological Surgeons. 1
Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19
Prudencio, Mercedes , Marquez, Christopher P. , Jansen‐West, Karen , Franco-Mesa, Camila , White, Launia J. , Dunmore, Judith A. , Cook, Casey , Lilley, Meredith T. , Song, Yuping , Harlow, Caroline , Oskarsson, Björn , Nicholson, Katharine, Hoyne, Jonathan , Petrucelli, Leonard , Marquez, Christopher P , Jansen-West, Karen R , Franco-Mesa, Camila , White, Launia J , Dunmore, Judith A , Cook, Casey N , Harlow, Caroline F , Oskarsson, Björn , Wszolek, Z.K. , Hickson, LaTonya J , O'Horo, John C , Hoyne, Jonathan B , Gendron, Tania F , Meschia, James F , Petrucelli, Leonard , Prudencio, Mercedes , Lilley, Meredith T , Erben, Young , Heckman, Michael G. , Wszołek, Zbigniew K. , Hickson, LaTonya J. , O’Horo, John C. , Gendron, Tania F. , Meschia, James F.

Mayo Clinic

Science Translational Medicine | June 15, 2021 | Volume: 13 | Issue: 602 | Pages: No page available

10.1126/scitranslmed.abi7643 | PMID 34131052 Get It

Hospitalized patients with COVID-19 show increased serum concentrations of neurofilament light chain that correlate with worse clinical outcomes.
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers
Amin, Mahul B. , Epstein, Jonathan I. , Hansel, Donna E. , Paner, Gladell P. , True, Larry, Bayder, Dilek, Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, Ondřej , Kaushal, Seema , Kunju, Lakshmi P., McKenney, Jesse K. , Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , Reuter, Victor, Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 196-208

10.1097/pap.0000000000000309 | PMID 34128484 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second of 2 manuscripts ensuing from this effort. Herein, we address the effective reporting of bladder cancer, focusing particularly on newly published data since the last 2016 World Health Organization (WHO) classification. In addition, this review focuses on the importance of reporting bladder cancer with divergent differentiation and variant (subtypes of urothelial carcinoma) histologies and the potential impact on patient care. We provide new recommendations for reporting pT1 staging in diagnostic pathology. Furthermore, we explore molecular evolution and classification, emphasizing aspects that impact the understanding of important concepts relevant to reporting and management of patients.
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia
Amin, Mahul B. , Epstein, Jonathan I. , True, Lawrence D. , Hansel, Donna E. , Paner, Gladell P. , Baydar, Dilek Ertoy , Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, O., Kaushal, Seema , Kunju, Lakshmi P., Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , McKenney, Jesse K. , Reuter, Victor E. , Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 179-195

10.1097/pap.0000000000000308 | PMID 34128483 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder cancer, emphasizing particularly on the newly accumulated evidence post-2016 World Health Organization (WHO) classification. The work is presented in 2 manuscripts. Here, in the first, we revisit the nomenclature and classification system used for grading flat and papillary urothelial lesions centering on clinical relevance, and on dilemmas related to application in routine reporting. As patients of noninvasive bladder cancer frequently undergo cystoscopy and biopsy in their typically prolonged clinical course and for surveillance of disease, we discuss morphologies presented in these scenarios which may not have readily applicable diagnostic terms in the WHO classification. The topic of inverted patterns in urothelial neoplasia, particularly when prominent or exclusive, and beyond inverted papilloma has not been addressed formally in the WHO classification. Herein we provide a through review and suggest guidelines for when and how to report such lesions. In promulgating these GUPS recommendations, we aim to provide clarity on the clinical application of these not so uncommon diagnostically challenging situations encountered in routine practice, while also importantly advocating consistent terminology which would inform future work.